{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:07:18Z","timestamp":1758632838259,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Echocardiogr"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12574-019-00446-9","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T11:15:02Z","timestamp":1571138102000},"page":"177-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6617-1521","authenticated-orcid":false,"given":"Katsuomi","family":"Iwakura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"446_CR1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1464-5491.2008.02581.x","volume":"25","author":"CR Elley","year":"2008","unstructured":"Elley CR, Kenealy T, Robinson E, et al. Glycated haemoglobin and cardiovascular outcomes in people with type 2 diabetes: a large prospective cohort study. Diabet Med. 2008;25:1295\u2013301.","journal-title":"Diabet Med"},{"issue":"938\u2013948","key":"446_CR2","first-page":"e2","volume":"162","author":"D Castagno","year":"2011","unstructured":"Castagno D, Baird-Gunning J, Jhund PS, et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J. 2011;162(938\u2013948):e2.","journal-title":"Am Heart J"},{"key":"446_CR3","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579\u201388.","journal-title":"Circulation"},{"key":"446_CR4","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","volume":"140","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. Circulation. 2019;140:e294\u2013324.","journal-title":"Circulation."},{"key":"446_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"Seferovi\u0107 PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:853\u201372.","journal-title":"Eur J Heart Fail"},{"key":"446_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"446_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"446_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"446_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2337\/diacare.26.3.855","volume":"26","author":"L Vaur","year":"2003","unstructured":"Vaur L, Gueret P, Lievre M, et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care. 2003;26:855\u201360.","journal-title":"Diabetes Care"},{"key":"446_CR10","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0735-1097(01)01230-X","volume":"37","author":"JE Liu","year":"2001","unstructured":"Liu JE, Palmieri V, Roman MJ, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the strong heart study. J Am Coll Cardiol. 2001;37:1943\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"446_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amjcard.2009.09.041","volume":"105","author":"D Aguilar","year":"2010","unstructured":"Aguilar D, Deswal A, Ramasubbu K, et al. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol. 2010;105:373\u20137.","journal-title":"Am J Cardiol"},{"key":"446_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/CIRCHEARTFAILURE.114.001990","volume":"8","author":"H Skali","year":"2015","unstructured":"Skali H, Shah A, Gupta DK, et al. Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the atherosclerosis risk in the community study. Circ Heart Fail. 2015;8:448\u201354.","journal-title":"Circ Heart Fail"},{"key":"446_CR13","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.2337\/dc11-0191","volume":"34","author":"M De Marco","year":"2011","unstructured":"De Marco M, de Simone G, Roman MJ, et al. Cardiac geometry and function in diabetic or prediabetic adolescents and young adults: the strong heart study. Diabetes Care. 2011;34:2300\u20135.","journal-title":"Diabetes Care"},{"key":"446_CR14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/db15-0627","volume":"65","author":"E Levelt","year":"2016","unstructured":"Levelt E, Mahmod M, Piechnik SK, et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes. 2016;65:44\u201352.","journal-title":"Diabetes"},{"key":"446_CR15","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/hrt.2005.079350","volume":"92","author":"S Moir","year":"2006","unstructured":"Moir S, Hanekom L, Fang Z-Y, et al. Relationship between myocardial perfusion and dysfunction in diabetic cardiomyopathy: a study of quantitative contrast echocardiography and strain rate imaging. Heart. 2006;92:1414\u20139.","journal-title":"Heart"},{"key":"446_CR16","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.amjcard.2009.06.063","volume":"104","author":"ACT Ng","year":"2009","unstructured":"Ng ACT, Delgado V, Bertini M, et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2009;104:1398\u2013401.","journal-title":"Am J Cardiol"},{"key":"446_CR17","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jcmg.2018.03.015","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang H, Huynh Q, et al. Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus: optimal parameters for prediction of heart failure. JACC Cardiovasc Imaging. 2018;11:1390\u2013400.","journal-title":"JACC Cardiovasc Imaging"},{"key":"446_CR18","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","volume":"55","author":"LJMM Boonman-De Winter","year":"2012","unstructured":"Boonman-De Winter LJMM, Rutten FH, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154\u201362.","journal-title":"Diabetologia"},{"key":"446_CR19","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jacc.2017.07.792","volume":"70","author":"L Ernande","year":"2017","unstructured":"Ernande L, Audureau E, Jellis CL, et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol. 2017;70:1704\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"446_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCIMAGING.115.003643","volume":"9","author":"M Leung","year":"2016","unstructured":"Leung M, Wong VW, Hudson M, et al. Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus. Circ Cardiovasc Imaging. 2016;9:1\u20139.","journal-title":"Circ Cardiovasc Imaging"},{"key":"446_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-5996-6-103","volume":"6","author":"KC Nogueira","year":"2014","unstructured":"Nogueira KC, Furtado M, Fukui RT, et al. Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor\u2014a pilot study. Diabetol Metab Syndr. 2014;6:1\u20137.","journal-title":"Diabetol Metab Syndr."},{"key":"446_CR22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00380-014-0509-4","volume":"30","author":"T Fujiwara","year":"2015","unstructured":"Fujiwara T, Yoshida M, Nakamura T, et al. Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients. Heart Vessels. 2015;30:696\u2013701.","journal-title":"Heart Vessels"},{"key":"446_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12933-015-0242-z","volume":"14","author":"H Oe","year":"2015","unstructured":"Oe H, Nakamura K, Kihara H, et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:2\u20135.","journal-title":"Cardiovasc Diabetol."},{"key":"446_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/1479164116629352","volume":"13","author":"M Leung","year":"2016","unstructured":"Leung M, Leung DY, Wong VW. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: a pilot study. Diabetes Vasc Dis Res. 2016;13:236\u201343.","journal-title":"Diabetes Vasc Dis Res"},{"key":"446_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-017-0546-2","volume":"16","author":"H Yamada","year":"2017","unstructured":"Yamada H, Tanaka A, Kusunose K, et al. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc Diabetol. 2017;16:1\u201312.","journal-title":"Cardiovasc Diabetol"},{"key":"446_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","volume":"6","author":"JJV McMurray","year":"2018","unstructured":"McMurray JJV, Ponikowski P, Bolli GB, et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail. 2018;6:8\u201317.","journal-title":"JACC Heart Fail"},{"key":"446_CR27","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.2337\/dc16-1312","volume":"39","author":"S Verma","year":"2016","unstructured":"Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39:e212\u20133.","journal-title":"Diabetes Care"},{"key":"446_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-017-0656-x","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Kayama Y, et al. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17:1\u201312.","journal-title":"Cardiovasc Diabetol"},{"key":"446_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17:1\u20138.","journal-title":"Cardiovasc Diabetol"},{"key":"446_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042375","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042375 .","journal-title":"Circulation"}],"container-title":["Journal of Echocardiography"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12574-019-00446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12574-019-00446-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12574-019-00446-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T01:09:08Z","timestamp":1721869748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12574-019-00446-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s12574-019-00446-9","relation":{},"ISSN":["1349-0222","1880-344X"],"issn-type":[{"type":"print","value":"1349-0222"},{"type":"electronic","value":"1880-344X"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"16 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author received honoraria from AstraZeneca, Ono pharmaceutical, Boehringer-Ingelheim, Eli Lilly and Company, Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi-Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}